The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation
Alexa S. Green(Délégation Paris 5), Jérôme Tamburini(University of Geneva), Patrick Mayeux(Université Paris Cité), Mireille Lambert(Inserm), Sophie Park(Centre National de la Recherche Scientifique), Norbert Ifrah(Inserm), Marc Foretz(Institut Cochin), Olivier Boyer(Centre Hospitalier Universitaire de Rouen), Benoı̂t Viollet(Institut Cochin), Thiago Trovati Maciel(Inserm), Nicolas Chapuis(Délégation Paris 5), Christophe Arnoult(Centre Hospitalier Universitaire de Rouen), Olivier Hermine(Délégation Paris 5), Didier Bouscary(Centre National de la Recherche Scientifique), Valérie Bardet(Délégation Paris 5), Ivan Cruz Moura(Délégation Paris 5), Catherine Lacombe(Centre National de la Recherche Scientifique), François Dreyfus(Université Paris-Sud), Lise Willems(Centre National de la Recherche Scientifique)
Cited by 196
Related Papers
Metformin: From Mechanisms of Action to Therapies
|Cell Metabolism|2014|1.5k
Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin
|New England Journal of Medicine|2002|1.2k
Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state
|Journal of Clinical Investigation|2010|1.2k
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2017|736
Metformin: update on mechanisms of action and repurposing potential
|Nature Reviews Endocrinology|2023|621